Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS 1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS 1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IosH2 (Primary) ; Pembrolizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors ImmunOs Therapeutics

Most Recent Events

  • 07 Oct 2024 Planned End Date changed from 31 Mar 2025 to 31 May 2025.
  • 07 Oct 2024 Planned primary completion date changed from 31 May 2024 to 31 May 2025.
  • 17 Sep 2024 According to an ImmunOs Therapeutics media release, Proceeds from the Series C will be used to further fund the ongoing clinical trial of ImmunOs' lead program IOS-1002 to completion of the Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD's anti-PD1 therapy KEYTRUDA(pembrolizumab). and company look forward to enable more exciting data from the clinical trials of IOS-1002.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top